Primary Outcomes:

Primary Outcome 1 - Measure: Adverse events, including Dose Limiting Toxicities (DLTs) and Serious Adverse Events (SAEs)

Primary Outcome 1 - Time Frame: Day 7 through Day 28

Primary Outcome 2 - Measure: Phase Ib/II starting dose for ACE1702

Primary Outcome 2 - Time Frame: Through study completion, up to 1 year

Condition:

• Locally Advanced Solid Tumor
• Metastatic Cancer
• Solid Tumor
• HER2-positive Gastric Cancer
• HER2-positive Metastatic Breast Cancer

Eligibility

Criteria:
Inclusion Criteria:

- Signed informed consent

- Subjects must be ≥ 18 years of age

- Subject with advanced or metastatic solid tumors that is not amenable to surgical
resection and is not eligible or has refused other approved therapeutic options that
have demonstrated clinical benefit.

- Histologically confirmed HER2 expression.

- Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 1

- Measurable or non-measurable evaluable disease according to RECIST 1.1

- Adequate hematologic and end-organ function at baseline

- Oxygen saturation via pulse oxygenation ≥ 90% at rest on room air

Exclusion Criteria:

- Untreated central nervous system (CNS) metastases

- Multiple primary malignancies

- Clinically significant cardiovascular disease such as New York Heart Association
(NYHA) cardiac disease (class III or greater)

- Pregnant or lactating female

- Serious, uncontrolled medical disorder that, in the opinion of the Investigator, would
impair the ability of the subject to receive study treatment

- History of autoimmune or immune mediated symptomatic disease

- Any anti-cancer chemotherapy or targeted small molecule therapy, or experimental
therapy/device within 4 weeks or 5 half-lives of the drug prior to planned start of
study
Show More

Gender: All

Minimum Age: 18 Years

Maximum Age: N/A

Healthy Volunteers: No